Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AF 05

Next Previous
Drug Profile

AF 05

Alternative Names: AF-05; AF-5

Latest Information Update: 27 Aug 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute of Materia Medica
  • Developer Beijing Collab Pharma; Institute of Materia Medica
  • Class Sesquiterpenes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Anxiety disorders

Most Recent Events

  • 27 Aug 2019 AF 05 is still in phase II for Anxiety disorder in China (Beijing Collab Pharma website, August 2019)
  • 01 Mar 2016 Phase-II clinical trials in Anxiety disorders in China (unspecified route)
  • 30 Nov 2009 Phase-I clinical trials in Anxiety disorders in China (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top